Dynamic personalized prediction of the individual liver-related risk after sustained viral response in HCV patients
- PMID: 36891763
- DOI: 10.1111/jvh.13830
Dynamic personalized prediction of the individual liver-related risk after sustained viral response in HCV patients
Abstract
Sustained viral response (SVR) significantly improves the prognosis in patients with hepatitis C virus (HCV) chronic infection but does not totally alleviate the risk of liver-related complications (LRC). We aimed to evaluate whether the dynamics of multiple measurements of simple parameters after SVR enable the development of a personalized prediction of prognosis in HCV patients. HCV mono-infected patients who experienced SVR in two prospective cohorts (ANRS CO12 CirVir cohort: derivation set; ANRS CO22 HEPATHER cohort: validation set) were included. The study outcome was LRC, a composite criterion including decompensation of cirrhosis and/or hepatocellular carcinoma. Joint latent class modelling accounting for both biomarker trajectory and event occurrence during follow-up was developed in the derivation set to compute individual dynamic predictions, with further evaluation in the validation set. In the derivation set (n = 695; 50 LRC during the median 3.8 [1.6-7.5] years follow-up), FIB4 was identified as a biomarker associated with LRC occurrence after SVR. Joint modelling used sex and the dynamics of FIB4 and diabetes status to develop a personalized prediction of LRC. In the validation set (n = 7064; 273 LRC during the median 3.6 [2.5-4.9] years follow-up), individual dynamic predictions from the model accurately stratified the risk of LRC. Time-dependent Brier Score showed good calibration that improved with the accumulation of visits, justifying our modelling approach considering both baseline and follow-up measurements. Dynamic modelling using repeated measurements of simple parameters predicts the individual residual risk of LRC and improves personalized medicine after SVR in HCV patients.
Keywords: FIB4; chronic viral hepatitis C; liver-related complication; personalized medicine; sustained viral response.
© 2023 John Wiley & Sons Ltd.
References
REFERENCES
-
- Spearman W, Dusheiko G, Hellard M, Sonderup M. Hepatitis C. Lancet. 2019;394(10207):1451-1466.
-
- Carrat F, Fontaine H, Dorival C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393(10179):1453-1464.
-
- Backus L, Belperio P, Shahoumian T, Mole L. Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease. Hepatology. 2019;69(2):487-497.
-
- Sahakyan Y, Lee-Kim V, Bremner KE, Bielecki JM, Krahn MD. Impact of direct acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: systematic review and meta-analysis. J Viral Hepat. 2021;28(5):739-754.
-
- Ioannou G, Beste L, Green P, et al. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores. Gastroenterology. 2019;157(5):1264-1278.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
